Stay updated on Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed study information regarding the efficacy and safety of pembrolizumab + epacadostat for urothelial carcinoma, while adding new details about the study's unblinding process and collaborators.SummaryDifference15%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page.